bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
Stock data | 2024 | Change |
---|---|---|
Price | $1.83 | N/A |
Market Cap | $17.44M | N/A |
Shares Outstanding | 9.50M | N/A |
Employees | 14.00 | N/A |